利妥昔单抗治疗248例成人免疫性血小板减少症5年长期安全性与疗效
法国多中心前瞻性注册研究纳入248例接受利妥昔单抗治疗的成人ITP患者,随访中位68.4个月,严重感染发生率为2/100患者年,60个月持续缓解率29.4%,既往对糖皮质激素一过性应答是持续缓解的唯一显著相关因素。
要点
- 严重感染发生率低(2/100患者年),5例出现重度低丙种球蛋白血症。
- 初始应答后复发者再治疗应答率达92%,可作为有效且安全的选择。
核心结论
- 利妥昔单抗在成人ITP中具有良好的长期安全性,5年持续缓解率约29.4%,仍是重要的治疗选择,再治疗有效且安全。
研究设计与样本
- 法国多中心前瞻性注册研究ITP-ritux,纳入248例接受利妥昔单抗治疗的成人ITP患者,随访5年,中位随访68.4个月(53.7-78.5)。
主要发现
- 严重感染发生率为2/100患者年。
- 5例患者在末次利妥昔单抗输注后15至31个月出现重度低丙种球蛋白血症(<5 g/L)。
- 共25例患者死亡,中位年龄80岁(69.5-83.9),死亡率2.3/100患者年;仅3例感染相关死亡(发生于输注后12至14个月)可能部分与利妥昔单抗有关。
- 随访60个月时73例(29.4%)患者获得持续缓解。
关键数值与推荐
- 持续缓解定义为随访60个月时仍维持应答,共73例(29.4%)。
- 重度低丙种球蛋白血症定义为<5 g/L。
- 再治疗应答率为92%,54%的患者应答持续时间更长。
临床怎么用
- 利妥昔单抗可作为成人ITP的二线治疗选择,尤其适用于既往对糖皮质激素有一过性应答的患者。
- 治疗后可发生重度低丙种球蛋白血症,需长期监测免疫球蛋白水平。
- 初始应答后复发者可考虑利妥昔单抗再治疗。
局限性
- 本研究为注册研究,非随机对照试验,可能存在选择偏倚。
- 部分死亡与感染的相关性判断为可能,无法完全归因于利妥昔单抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab is a second-line option in adults with immune thrombocytopenia (ITP), but the estimated 5-year response rate, only based on pooled retrospective data, is about 20%, and no studies have focused on long-term safety. We conducted a prospective multicenter registry of 248 adults with ITP treated with rituximab with 5 years of follow-up to assess its long-term safety and efficacy. The median follow-up was 68.4 [53.7-78.5] months. The incidence of severe infections was only 2/100 patient-years. Profound hypogammaglobulinemia (<5 g/L) developed in five patients at 15 to 31 months after the last rituximab infusion. In total, 25 patients died at a median age of 80 [69.5-83.9] years, corresponding to a mortality rate of 2.3/100 patient-years. Only three deaths related to infection that occurred 12 to 14 months after rituximab infusions could be due in part to rituximab. At 60 months of follow-up, 73 (29.4%) patients had a sustained response. On univariate and multivariate analysis, the only factor significantly associated with sustained response was a previous transient response to corticosteroids (P = .022). Overall, 24 patients with an initial response and then relapse received retreatment with rituximab, which gave a response in 92%, with a higher duration of response in 54%. As a result of its safety profile and its sustained response rate, rituximab remains an important option in the current therapeutic armamentarium for adult ITP. Retreatment could be an effective and safe option.
引用
- Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019. PMID: 31489694. doi:10.1002/ajh.25632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。